Type 2 diabetes mellitus (T2D) and chronic obstructive pulmonary disease (COPD) are prevalent chronic conditions that frequently coexist, contributing to significant morbidity and healthcare burden worldwide [1]. The pathophysiological interplay between those diseases is complex, involving shared risk factors, such as systemic inflammation, oxidative stress, and metabolic dysregulation [1]. Individuals with T2D are at an increased risk of developing COPD and experiencing more frequent and severe exacerbations, which underscores the importance of optimizing therapeutic strategies to mitigate this risk.
